Comparison of Belumosudil and Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD A Multicenter Randomized Study with Treatment Switch for Pretreated Patients
Led by First Affiliated Hospital of Zhejiang University · Updated on 2026-08-31
170
Participants Needed
1
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are comparing two second-line treatments, ruxolitinib and belumosudil, for patients with steroid-refractory or breakthrough hepatic chronic graft-versus-host disease cGVHD following allogeneic hematopoietic stem cell transplantation allo-HSCT. The study aims to determine differences in liver response rates, safety, tolerability, steroid reduction, and long-term outcomes between these treatments. Two patient groups are included those new to these drugs and those switching treatments due to lack of response or progression.
Participants will receive assigned oral treatments based on their group and randomization. Cohort 1 includes patients who have not previously taken either drug and are randomized to one. Cohort 2 involves patients who switch from one drug to the other if their hepatic cGVHD worsens or does not respond. Treatments follow standard approved dosing schedules. The study includes a 24-week primary treatment period with ongoing follow-up until disease progression or treatment discontinuation.
During the study, participants undergo regular monitoring for treatment effectiveness and safety, including liver function tests, cGVHD scoring, and adverse event tracking. Blood samples are collected at baseline and various times on treatment for biomarker research. Researchers assess liver response at 24 weeks as the primary outcome, with secondary outcomes including response duration, survival, steroid tapering, quality of life, and safety. The total participation time extends up to two years for some assessments.
CONDITIONS
Brief Title
Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD
Research Team
F
Fei Gao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborating Sponsor
Who Can Participate
Age: 12Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age 12 years or older at time of consent
Received allogeneic hematopoietic stem cell transplantation
Diagnosed with hepatic cGVHD per 2014 NIH criteria
ECOG performance status 0 to 2
Able to take oral medication
Life expectancy of at least 6 months
Adequate organ function including ANC ≥ 1.0×10⁹/L, platelets ≥ 50×10⁹/L, and creatinine clearance ≥ 30 mL/min
Negative pregnancy test for females of childbearing potential and agreement to use contraception; males agree to contraception
Willing and able to provide informed consent and follow study requirements
Cohort 1: Steroid-refractory with progressive disease or persistent cGVHD on stable steroids
Cohort 2: New or progressing hepatic cGVHD after stable ruxolitinib or belumosudil for other-organ cGVHD with no prior exposure to the other drug
You will not qualify if you...
Receiving newly started systemic cGVHD treatment other than stable corticosteroids and calcineurin inhibitors
Active uncontrolled acute GVHD grade 2 or higher
Active viral hepatitis or HIV infection
Liver abnormalities due to other causes such as drug-induced injury, autoimmune hepatitis, alcoholic liver disease, or biliary obstruction
Severe cardiovascular or cerebrovascular disease including NYHA class 3 or above
Respiratory failure requiring ventilation or severe uncontrolled lung disease
Inability to take oral medication or severe gastrointestinal dysfunction affecting absorption
Significant neurological or psychiatric conditions
Relapsed primary malignancy or post-transplant lymphoproliferative disorder
History of other cancers except certain cured or stable cases
ECG abnormalities with prolonged QTcF interval
Known alcohol or drug dependence
Pregnant or breastfeeding women
Allergy to study drugs or their ingredients
Any condition affecting safety or compliance per investigator judgment
Cohort 1: Prior treatment with JAK or ROCK2 inhibitors or recent investigational therapies
Cohort 2: Prior exposure to both study drugs
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 24 weeks
Participants receive assigned oral treatment with either ruxolitinib or belumosudil, or switch drugs if their hepatic cGVHD worsens during the study.
Regular visits for efficacy and safety monitoring
Follow-up
Duration - Up to 2 years
Participants are monitored after treatment for disease progression, survival, and long-term outcomes up to two years.
Periodic assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Study of GT729 Cell Injection for Treating Refractory or Relapsed Chronic Graft-versus-Host Disease cGVHD in Adults Aged 18 to 65
Phase I Study of Norovirus-Specific T-Cell Therapy for Chronic Norovirus Infection in Immunocompromised Patients After Stem Cell or Organ Transplant or With Primary Immunodeficiency
Phase IIb Study of Axatilimab Combined With Extracorporeal Photopheresis ECP for Treating Chronic Graft-versus-Host Disease
Comparison of Belumosudil and Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD A Multicenter Randomized Study with Treatment Switch for Pretreated Patients
Open-Label Study of BPC2001 to Prevent Acute Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation
Oral Sodium Copper Chlorophyllin to Reduce Severe Oral Mucositis in Patients Receiving Myeloablative Total Body Irradiation Before First Allogeneic Stem Cell Transplant
Immune Response Study to First CMV Reactivation in Adults After Allogeneic Stem Cell Transplant
Feasibility Study of Structured Outpatient Palliative Care After Allogeneic Hematopoietic Stem Cell Transplantation to Support Recovery
Comparing Inspiratory Muscle Training Methods to Improve Lung and Muscle Function
in Adults Undergoing Hematopoietic Stem Cell Transplantation
Comparing Proton Pump Inhibitors and Gastric Protective Agents to Prevent Acute Graft-versus-Host Disease After Stem Cell Transplant
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.
An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent/steroid-resistant chronic GVHD.
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
Madan H Jagasia, Hildegard T Greinix, Mukta Arora...